Quanterix is a life sciences company that develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific.
Quanterix is digitizing biomarker analysis with the goal of advancing the science of precision health. It’s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease.
Quanterix was founded in 2007 as Digital Genomics, and changed its name to Quanterix in August 2007. The company has it's headquartered in Lexington, Massachusetts.
Quanterix’ technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come.
Quanterix's products include kits, such as beads, capture and detector reagents, enzyme reagents, and enzyme substrates to run tests; and consumables, such as proprietary Simoa disks, cuvettes, and disposable tips. In addition, it offers contract research services, including sample testing, homebrew assay development, and custom development services.
Quanterix has collaboration agreements with DestiNA Genomics to focus on the development of a nucleic acid assay for direct detection and quantification of the liver toxicity biomarker microRNA-122; and OncoGenesis Corp to develop a protein biomarker diagnostic test for cervical health using its Simoa Planar Technology.
Quanterix is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures among others. The company went public in Dec 6, 2017, at a IPO Valuation of $317M.